MBK Healthcare Management Pte Ltd (“MHM”), a wholly owned subsidiary of Mitsui & Co., Ltd. (“Mitsui”), has sourced and supported Mitsui’s participation in a US$4mn Series Seed round in Aidar Health, Inc. (“Aidar”) as the lead investor.  Aidar is a United States based health technology and digital medicine company, and MHM will continue to support Mitsui through managing this investment.

 

Aidar develops and designs clinically-validated software and breath and saliva-based biosensors, to deliver evidence-based digital interventions for various chronic diseases. Aidar’s FDA cleared MouthLab is capable of measuring over 10 vital health parameters in a minute, all in a single hand-held device. This will help reduce multiple friction points that chronic disease patients currently face as they monitor their health on a daily basis.

 

Aidar’s focus on the individual’s experience aligns this investment with Mitsui’s goal of leading and accelerating a paradigm shift in healthcare from a treatment-centered to a prevention-centered approach, and from a hospital-centered to individual-centered value-based healthcare. MHM aims to facilitate collaborations between Mitsui’s existing portfolio companies and Aidar, as well as help Aidar grow and strengthen their business outside of the United States.

 

MHM was established in 2016 as Mitsui’s dedicated healthcare operating platform. As the largest shareholder of IHH Healthcare Berhad (IHH, KLSE: 5225, SGX: Q0F), a leading premium healthcare provider operating 80 hospitals in 10 countries with more than 15,000 licensed beds, MHM’s mission is to create long-term value and to grow the portfolio within the healthcare ecosystem of Mitsui.